Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix

Part of paid clinical trials in Houston, Texas.

Sponsor: M.D. Anderson Cancer Center
Study ID: NCT00626561
Phase: PHASE2
Status: Terminated

Conditions

Eligibility Criteria

Sex: FEMALE
Age: N/A - N/A
Healthy Volunteers: Not accepted

Interventions

Bevacizumab — DRUG
10 mg/kg IV twice weekly on days 1 and 15.
Paclitaxel — DRUG
60 mg/m\^2 IV weekly on days 1, 8, 15, and 22.

Study Details

Objectives: Primary: To estimate the efficacy of bevacizumab and paclitaxel in patients with recurrent small cell, large cell, and neuroendocrine cervical and uterine cancers, as measured by progression-free survival. Secondary: 1. To estimate the efficacy of bevacizumab and paclitaxel in patients with recurrent small cell, large cell, and neuroendocrine cervical and uterine cancers, as measured by overall survival. 2. To determine the response rates in patients with recurrent small cell, large cell, and neuroendocrine cervical and uterine cancers when treated with bevacizumab and paclitaxel. 3. To characterize the quality of life (QoL) in patients with recurrent small cell, large cell, and neuroendocrine cervical and uterine cancers when treated with bevacizumab and paclitaxel. 4. To determine the nature and degree of toxicity in patients with advanced or recurrent small cell, large cell, or neuroendocrine cervical and uterine cancers when treated with bevacizumab and paclitaxel.